Ab­b­Vie inks deal for Med­in­cell's long-act­ing in­jectable plat­form worth up to $1.9B

Ab­b­Vie is bet­ting more than $1.9 bil­lion on a French biotech’s long-act­ing in­jectable tech­nol­o­gy.

The deal gives Med­in­cell $35 mil­lion up­front and up to $1.9 bil­lion in mile­stones for the de­vel­op­ment of up to six ther­a­peu­tic long-act­ing prod­ucts. Med­in­cell said on Tues­day the work will span “mul­ti­ple ther­a­peu­tic ar­eas and in­di­ca­tions,” but de­clined to go in­to fur­ther de­tail. Ab­b­Vie al­so de­clined to com­ment on its ther­a­peu­tic fo­cus.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER